
MYPROSTATESCORE 2.0
Clear Results. Confident Decision.
MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer by analyzing a comprehensive array of 18 unique gene transcripts. Our algorithm has been developed to optimize diagnostic accuracy and provide clinical flexibility, allowing MPS2 to be run as a biomarker-only test or inclusive of clinical risk factors, depending on provider preference. Receive individualized reports with results tailored to unique patient and clinical context.
Stay Up To Date
Resources
Industry news, men’s health information, and expert prostate cancer and risk assessment research.
Cancer Today Spotlights Lynx Dx’s MPS2 as a Breakthrough At-Home Prostate Cancer Test
In a recent feature, Cancer Today explores how MyProstateScore 2.0 [...]
Newly Published Analytical Validation Reinforces Accuracy and Precision of MyProstateScore 2.0
A new peer-reviewed study published in Diagnostics confirms the analytical [...]
Bringing Accurate and Flexible Prostate Cancer Insights to AUA2025!
Join the Lynx Dx team at AUA2025, the American Urological Association's annual meeting, April 26-29, 2025.